Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 5.32B 787M 684M 637M 585M 1.1B 75.11B 1.12B 7.5B 2.95B 37.39B 2.96B 2.89B 125B P/E 2026 *
5.56x
P/E 2027 * 4.96x
Enterprise Value 5.32B 787M 684M 637M 585M 1.1B 75.11B 1.12B 7.5B 2.95B 37.39B 2.96B 2.89B 125B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.63x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
3 years 18.53
Extreme 18.53
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 2019-11-30
Comptroller/Controller/Auditor 53 2011-01-31
Director TitleAgeSince
Chairman 70 2002-08-13
Director/Board Member 62 2002-08-13
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%-.--% - - 802M
-0.53%+1.87%+14.81%+74.83% 50.29B
-1.81%+1.69%+53.40%+106.05% 37.24B
+0.46%+5.76%-5.53%+25.08% 12.41B
+1.05%+1.17%+13.23%+75.93% 11.65B
-1.14%+0.57%+32.24%+132.30% 9.17B
-2.99%-0.60%+43.05%-8.54% 7.24B
+0.51%+1.46%+12.17%+32.88% 6.8B
+1.99%+1.31%+3.73%+179.67% 6.47B
+0.39%-4.81%-34.14%-1.07% 5.46B
Average +0.18%+1.96%+14.77%+68.57% 16.3B
Weighted average by Cap. -0.59%+2.71%+22.81%+77.97%

Financials

2026 *2027 *
Net sales 3.03B 449M 390M 363M 334M 630M 42.88B 640M 4.28B 1.68B 21.35B 1.69B 1.65B 71.57B 3.26B 483M 420M 391M 359M 678M 46.11B 688M 4.61B 1.81B 22.96B 1.81B 1.77B 76.98B
Net income 956M 142M 123M 115M 105M 199M 13.51B 202M 1.35B 530M 6.73B 531M 520M 22.55B 1.07B 159M 138M 128M 118M 223M 15.15B 226M 1.51B 594M 7.54B 596M 583M 25.29B
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,822
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
7.029CNY
Average target price
7.943CNY
Spread / Average Target
+13.00%

Quarterly revenue - Rate of surprise